# Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

> **NCT07243626** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 25 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)

## Key facts

- **NCT ID:** NCT07243626
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-06-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243626, "Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07243626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*